Carcinoma in situ of bladder
Information
- Disease name
- Carcinoma in situ of bladder
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01304173 | Completed | Retrospective Chart Review of Valstar | March 2011 | October 2011 | |
| NCT05375903 | Recruiting | Phase 1 | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | June 1, 2022 | December 2025 |
| NCT02901548 | Terminated | Phase 2 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | February 16, 2017 | September 7, 2021 |
| NCT03335059 | Terminated | Phase 3 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. | April 4, 2019 | February 26, 2020 |